NanoViricides prices 3.57M shares at $1.68 in registered direct offering

NanoViricides (NNVC) entered into a securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock at a purchase price of $1.68 per share in a registered direct offering. The gross proceeds from the Offering are expected to be approximately $6M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell Series A warrants to purchase up to 3,571,429 shares of common stock and Series B warrants to purchase up to 3,571,429 shares of common stock. The Series A Warrants will have an exercise price of $1.75 per share, will be exercisable after 6 months from date of issuance, and will expire 2 years following the issuance date. The Series B Warrants will have an exercise price of $2.00 per share, will be exercisable after 6 months from date of issuance, and will expire 5.5 years following the issuance date. The exercise price of the Series B Warrants represents approximately a 20% premium to the closing price for the Company’s common stock on November 10, 2025. The closing of the Offering is expected to occur on or about November 12, 2025, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the offering.